PFE vs. NVO: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2315429/pfe-vs-nvo-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2315429
Aug 02, 2024 - PFE vs. NVO: Which Stock Is the Better Value Option?
0
This Could Send Ozempic's Sales Potential to a Whole Other Level
https://www.fool.com/investing/2024/07/28/this-could-send-ozempics-sales-potential-to-whole/?source=iedfolrf0000001
Jul 28, 2024 - Ozempic could pile up a lot more indications in the years ahead.
0
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2307305/novo-nordisk-nvo-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2307305
Jul 23, 2024 - In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
0
Here's My Top Growth Stock to Buy Right Now
https://www.fool.com/investing/2024/07/20/heres-my-top-growth-stock-to-buy-right-now/?source=iedfolrf0000001
Jul 20, 2024 - Hims & Hers shares have multi-bagger growth potential over the years to come.
0
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
https://www.zacks.com/stock/news/2304649/novo-nordisk-lilly-slide-on-roche-s-obesity-drug-study-data?cid=CS-ZC-FT-analyst_blog|industry_focus-2304649
Jul 18, 2024 - Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
0
2 Incredibly Cheap Growth Stocks to Buy Now
https://www.fool.com/investing/2024/07/14/2-incredibly-cheap-growth-stocks-to-buy-now/?source=iedfolrf0000001
Jul 14, 2024 - Price is just one factor to consider.
0
PFE or NVO: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2300998/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2300998
Jul 12, 2024 - PFE vs. NVO: Which Stock Is the Better Value Option?
0
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
https://www.zacks.com/stock/news/2300869/pharma-stock-roundup-lly-to-buy-morphic-pfe-advances-obesity-drug-development?cid=CS-ZC-FT-analyst_blog|stock_roundup-2300869
Jul 12, 2024 - Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.
0
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
https://www.zacks.com/stock/news/2300219/novo-nordisk-nvo-soars-38-ytd-how-should-you-play-the-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2300219
Jul 11, 2024 - Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
0
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
https://www.zacks.com/stock/news/2300248/novo-nvo-gets-crl-from-fda-for-weekly-basal-insulin-icodec?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2300248
Jul 11, 2024 - Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
0